Tracer library / [131I]I-T-ZHP1

[131I]I-T-ZHP1

Also written as [I-131]I-T-ZHP1

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: trastuzumab-PNA conjugate (antibody-peptide nucleic acid conjugate)
Target / mechanism: HER2, via PNA-mediated pretargeting of trastuzumab PMID 33247180
Clinical application: HER2-expressing cancer (radionuclide pretargeting imaging/therapy) PMID 33247180
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	92 ± 5%	>95%	T-ZHP1 (trastuzumab-ZHP1 conjugate) Herceptin, Roche, Mississauga, ON	33247180 2020 Sci Rep radiolabeled with [131I]NaI using direct radioiodination as described earlier - The radiochemical yields were 92 ± 5% and 90 ± 7% for T-ZHP1 and CA, respectively.

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Herceptin, Roche, Mississauga
Typical final purification: —

Need this precursor?We can point you to suppliers for [131I]I-T-ZHP1, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33247180. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33247180: 'T-ZHP1 (trastuzumab-ZHP1 conjugate)'.